Our Research
Discover our recent findings, catch up with news, and review in-depth resources.
Case Studies
A New Sensitivity Benchmark: Ultra-Sensitive Hybrid LC-MS/MS for siRNA Quantitation in Human Plasma
Resolian developed the first hybrid LC-MS/MS method to achieve 50 pg/mL sensitivity for a duplex siRNA and its N-1 metabolite in human plasma, setting a new benchmark for regulated siRNA bioanalysis.
Blog
Strategies for ADC Bioanalysis: Building for Complexity, Designing for the Future
Resolian’s Andy Xue on what makes ADC bioanalysis uniquely demanding, and how the team builds scalable, drug-tolerant methods across ADCs, PDCs, and AOCs.
Blog
LC-MS for Protein Biomarkers: Precision Where Immunoassays Fall Short
Resolian’s Ashley Phillips on why LC-MS outperforms immunoassays for protein biomarkers, from isoform differentiation to drug-tolerant assay design.
Case Studies
Faster, Simpler Oligonucleotide Quantitation: An Extraction-Free qPCR Workflow for Tissue and Plasma
Resolian developed an extraction-free, direct-to-qPCR workflow that accurately quantifies therapeutic oligonucleotides across plasma and multiple tissue types using a single calibration curve, reducing hands-on time and cost without compromising performance.
Case Studies
One Picogram Per Millilitre: Quantifying Free MMAE in Human Plasma for ADC Clinical Studies
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
Blog
Bioanalytical Partner for Biopharma Startups: 5 Proven Selection Criteria
Choosing a bioanalytical partner for biopharma startups? Follow these 5 proven criteria to protect your timeline, data quality, and regulatory readiness.
